To include your compound in the COVID-19 Resource Center, submit it here.

Emergent BioSolutions, TenX Biopharma deal

Emergent received exclusive, worldwide rights to zanolimumab from TenX Biopharma for infectious, cancer and autoimmune

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE